The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IMCR | +7.37% | N/A | N/A | -24% |
| S&P | +19.74% | +83.14% | +12.86% | +80% |
Immunocore Holdings Plc operates as a holding company. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.
Immunocore, Axsome Therapeutics, and Takeda are significantly outperforming the market this year.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $103.07M | 27.1% |
| Gross Profit | $101.77M | 27.9% |
| Gross Margin | 98.74% | 0.6% |
| Market Cap | $1.83B | 17.5% |
| Market Cap / Employee | $3.71M | 0.0% |
| Employees | 493 | 0.0% |
| Net Income | -$175.94K | -102.0% |
| EBITDA | -$6,334.72K | 16.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $498.41M | -7.3% |
| Accounts Receivable | $75.88M | 19.2% |
| Inventory | 5.7 | 25.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $433.98M | 0.5% |
| Short Term Debt | $1.88M | -96.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -2.66% | 3.0% |
| Return On Invested Capital | -29.46% | 36.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5,351.01K | -126.1% |
| Operating Free Cash Flow | -$4,603.87K | -121.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.93 | 4.14 | 4.18 | 4.74 | 8.65% |
| Price to Sales | 4.76 | 4.61 | 4.41 | 4.82 | -12.64% |
| Price to Tangible Book Value | 3.91 | 4.12 | 4.16 | 4.71 | 8.65% |
| Price to Free Cash Flow TTM | 70.65 | 59.17 | 55.04 | 640.74 | 717.01% |
| Enterprise Value to EBITDA | -60.10 | -410.56 | -79.36 | -217.01 | 33.77% |
| Free Cash Flow Yield | 1.4% | 1.7% | 1.8% | 0.2% | -87.76% |
| Return on Equity | -13.9% | -5.8% | -5.4% | -7.5% | -41.49% |
| Total Debt | $432.72M | $433.99M | $436.46M | $435.86M | -9.40% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
